Concepedia

Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis

Oliver J. McElvaney, Sonya L. Heltshe, Katherine Odem‐Davis, Natalie E. West, Don B. Sanders, B. Fogarty, Donald R. VanDevanter, Patrick A. Flume, Christopher H. Goss

Journal of Cystic Fibrosis · 2023 · 10 citations · 14 references

DOIFull text

Open access

Concepts

References

14

The central role of the propensity score in observational studies for causal effects

Paul R. Rosenbaum, Donald B. Rubin · Biometrika · 1983 · 31K citations · Full text

, , +16

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

Philip H. Quanjer, Sanja Stanojevic, Tim Cole et al. · European Respiratory Journal · 2012 · 5.9K citations · Full text

, , +12

Variable Selection for Propensity Score Models

M. Alan Brookhart, Sebastian Schneeweiß, Kenneth J. Rothman et al. · American Journal of Epidemiology · 2006 · 2.3K citations · Full text

, , +16

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +15

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Fredrick Van Goor, Sabine Hadidaꝉ, Peter D. J. Grootenhuis et al. · Proceedings of the National Academy of Sciences · 2011 · 1.1K citations · Full text

, , +13